Literature DB >> 12573872

Economic burden and quality of life impairment increase with severity of PD.

T Keränen1, S Kaakkola, K Sotaniemi, V Laulumaa, T Haapaniemi, T Jolma, H Kola, A Ylikoski, O Satomaa, J Kovanen, E Taimela, H Haapaniemi, H Turunen, A Takala.   

Abstract

PURPOSE: To define the interrelationship between cost-of-illness, quality of life (QoL) and Parkinson's disease (PD) severity in a common patient management setting in Finland.Scope. Two hundred and sixty consecutive outpatients with idiopathic PD participated. UPDRS, motor fluctuations, QoL, and the use of health care resources were measured. Direct and indirect costs were calculated.
CONCLUSIONS: There is a strong relationship between QoL or cost-of-illness on the one hand, and severity of PD on the other. Treatment policies capable of reducing or delaying motor fluctuations would be expected to increase QoL and reduce some of the economic burden of PD.

Entities:  

Mesh:

Year:  2003        PMID: 12573872     DOI: 10.1016/s1353-8020(02)00097-4

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  40 in total

Review 1.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 2.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 3.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Costs of illness in a Russian cohort of patients with Parkinson's disease.

Authors:  Yaroslav Winter; Sonja von Campenhausen; Georgy Popov; Jens P Reese; Jens Klotsche; Kai Bötzel; Eugene Gusev; Wolfgang H Oertel; Richard Dodel; Alla Guekht
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 5.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Cost of illness and its predictors for Parkinson's disease in Germany.

Authors:  Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Authors:  Huybert Groenendaal; Marcy L Tarrants; Christophe Armand
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

8.  Multiple balance tests improve the assessment of postural stability in subjects with Parkinson's disease.

Authors:  J V Jacobs; F B Horak; V K Tran; J G Nutt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

9.  The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson's disease.

Authors:  T H Haapaniemi; K A Sotaniemi; H Sintonen; E Taimela
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.